Sarepta stated that company intends to halt development on a number of medicinal products and lay off about 36% of its employees. By 2026, the business anticipates that the two actions taken combined will save over $400 million annually.
“Failure to adapt” to recent failures “would risk our long-term viability as an organization and decrease the opportunity to bring the greatest benefit to the greatest number of patients living with rare disease,” Sarepta CEO Doug Ingram stated on a conference call on Wednesday afternoon.
Strategic Restructuring
- A 36% workforce reduction, impacting approximately 500 employees, projected to generate approximately 120 million USD in annual cash cost savings in 2026
- Pipeline reprioritization expected to deliver approximately 300 million USD in annual non-personnel cost savings starting in 2026
- Over 100 million USD in cost savings anticipated through the end of 2025, net of estimated severance and one-time charges totaling 32-37 million USD
- Siga-nos -
